Medios AGMEDOF 88 Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus rates MEDOF with a GF Score™ of 88/100 and a GF Value™ of $68.42. The stock has 2 warning signs investors should review. Among 90 Medical Distribution companies, Medios AG ranks better than 53.33% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Medios AG's Debt-to-EBITDA or its related term are showing as below:
MEDOF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.81 Max: 3.71
Current: 2.29
During the past 13 years, the highest Debt-to-EBITDA Ratio of Medios AG was 3.71. The lowest was 0.02. And the median was 0.81.
MEDOF's Debt-to-EBITDA is ranked better than 53.33% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs MEDOF: 2.29
Medios AG (OTCPK:MEDOF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medios AG Debt-to-EBITDA Related Terms
Medios AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Medios AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Medios AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medios AG Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medios AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medios AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Medios AG (MEDOF) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medios AG. Over the past decade, Medios AG's Debt-to-EBITDA has ranged from 0.02 to 3.71. According to the industry distribution chart, Medios AG ranks #42 out of 90 companies in the Medical Distribution industry, placing it in the top 46.7%.
Is Medios AG's Debt-to-EBITDA too high?
Medios AG's current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 3.71. Based on the distribution chart, Medios AG ranks #42 out of 90 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Medios AG has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Medios AG's Debt-to-EBITDA compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medios AG ranks #42 out of 90 companies for Debt-to-EBITDA. This puts Medios AG in the upper half of its industry. The industry median Debt-to-EBITDA is 2.45. Historically, Medios AG's own Debt-to-EBITDA has ranged from 0.02 to 3.71 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medios AG. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medios AG's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medios AG stock overvalued right now?
Medios AG (MEDOF) has a current Debt-to-EBITDA of 0.00. The stock's GF Value™ is $68.42, compared to a current price of $50.00 — trading 26.9% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Medios AG's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Medios AG (MEDOF), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medios AG (MEDOF) Overvalued in 2026?
Based on GuruFocus' analysis, Medios AG stock appears to be undervalued.
The current stock price of $50.00 is trading 26.9% below its estimated GF Value™ of $68.42.
Key valuation signals for MEDOF:
Debt-to-EBITDA: 0.00
GF Value™: $68.42 vs. price of $50.00 (26.9% below fair value)
No single metric tells the full story. See the MEDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes: Patient-Specific Therapies: This area includes the compounding of medications on behalf of pharmacies in Germany. Pharmaceautical Supply: Medios is speciality pharma supplier company in germany, producing it own production facilities, hospitals, and Pharmacies. International Business: It includes all business and activities happening in international business.
88GF Score
Get the complete analysis for MEDOF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDOF has been successfully added to your 
